Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Marleen, Luten"'
Autor:
Jaap J. Zwaginga, Bronno van der Holt, Peter A. te Boekhorst, Bart J. Biemond, Mark-David Levin, René van der Griend, Anneke Brand, Sonja Zweegman, Hans F.M. Pruijt, Vera M.J. Novotny, Art Vreugdenhil, Marco R. de Groot, Okke de Weerdt, Elisabeth C.M. van Pampus, Tanja M. van Maanen-Lamme, Shulamiet Wittebol, Martin R. Schipperus, Matthijs H. Silbermann, Peter C. Huijgens, Marleen Luten, Rene Hollestein, Jan A.C. Brakenhoff, Jolanda G. Schrama, Fransje A.A. Valster, Gerjo A. Velders, Harry R. Koene
Publikováno v:
Haematologica, Vol 100, Iss 3 (2015)
Externí odkaz:
https://doaj.org/article/aa9c02bce86b43a7ad184444996b6a14
Autor:
Vassili Pastushenko, Rong Zhu, Marleen Luten, Thomas Perkmann, Hirotaka Isobe, Ulrich Salzer, Peter Hinterdorfer, Giel J. C. G. M. Bosman
Publikováno v:
Transfusion, 48, 451-62
Transfusion, 48, 3, pp. 451-62
Transfusion, 48, 3, pp. 451-62
Contains fulltext : 69440.pdf (Publisher’s version ) (Closed access) BACKGROUND: The release of vesicles by red blood cells (RBCs) occurs in vivo and in vitro under various conditions. Vesiculation also takes place during RBC storage and results in
Autor:
Pieternella J Lugtenburg, Josée M Zijlstra, Jeanette K Doorduijn, Lara H Böhmer, Marinus van Marwijk Kooy, Mels Hoogendoorn, Henriette W Berenschot, Aart Beeker, Fransje Valster, Harry C. Schouten, Marleen Luten, Henk Hofwegen, Dana A Chitu, Rolf E Brouwer, Gustaaf W van Imhoff
Publikováno v:
Blood. 126:2707-2707
Background: Patients with relapsed/ refractory diffuse large B-cell lymphoma (DLBCL) after- or not eligible for autologous stem cell transplantation (ASCT) have a poor prognosis. Treatment with salvage chemotherapy has generally been disappointing. I
Autor:
Hanneke C. Kluin-Nelemans, Joost J. Oudejans, W. L. J. Van Putten, Marleen Luten, G. W. van Imhoff, P. J. Lugtenburg, M. van Marwijk Kooy
Publikováno v:
Annals of Oncology, 22(7), 1595-1600. Elsevier Ltd.
Annals of Oncology, 22(7), 1595-1600. Oxford University Press
Annals of Oncology, 22(7), 1595-1600. Oxford University Press
Background: The prognosis of T-cell lymphoma is poor. To explore the addition of the monoclonal antibody alemtuzumab, we studied the efficacy and tolerability of an intensified alemtuzumab-chemotherapy combination for aggressive T-cell lymphoma in a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6796645af7a587d9d3c754c65e8d92b5
https://pure.eur.nl/en/publications/60d3a921-8e93-46bb-a44f-d9d8d3d0da86
https://pure.eur.nl/en/publications/60d3a921-8e93-46bb-a44f-d9d8d3d0da86
Autor:
Okke de Weerdt, Marleen Luten, René van der Griend, Anneke Brand, Ronnie van der Holt, Peter A. W. te Boekhorst, Jaap Jan Zwaginga, Sonja Zweegman, Art Vreughdenhil, Elisabeth C. M. Van Pampus, Bart J. Biemond, P. C. Huijgens, Mark Levin, Harry R. Koene, Rene Hollestein, Hans Pruijt
Publikováno v:
Blood, 116(21), 1042-1042
Zwaginga, J J, van der Holt, R, Biemond, B J, Boekhorst, P A W, Levin, M, Vreughdenhil, A, Huijgens, P C, Brand, A, van der Griend, R, Luten, M, Pruijt, H, de Weerdt, O, van Pampus, E, Zweegman, S, Hollestein, R & Koene, H R 2010, ' Interim Analysis on a Dutch HOVON Multicenter Randomized Open Label Phase II Trial on 3 Rituximab Dosing Schemes In Chronic ITP Patients: ' . < http://www.mendeley.com/research/interim-analysis-dutch-hovon-multicenter-randomized-open-label-phase-ii-trial-3-rituximab-dosing-sch >
Zwaginga, J J, van der Holt, R, Biemond, B J, Boekhorst, P A W, Levin, M, Vreughdenhil, A, Huijgens, P C, Brand, A, van der Griend, R, Luten, M, Pruijt, H, de Weerdt, O, van Pampus, E, Zweegman, S, Hollestein, R & Koene, H R 2010, ' Interim Analysis on a Dutch HOVON Multicenter Randomized Open Label Phase II Trial on 3 Rituximab Dosing Schemes In Chronic ITP Patients: ' . < http://www.mendeley.com/research/interim-analysis-dutch-hovon-multicenter-randomized-open-label-phase-ii-trial-3-rituximab-dosing-sch >
Abstract 2514 The overall short term effectivity of Rituximab in the treatment of ITP is reported to be around 50%. In most studies the traditional CD20 dosing scheme of 4 weekly interspaced 375 mg/m2 doses is used although other single-arm studies s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91342096607e19be0be834be6df27b24
http://hdl.handle.net/1887/118378
http://hdl.handle.net/1887/118378
Autor:
Jean-Louis H, Kerkhoffs, Wim L J, van Putten, Viera M J, Novotny, Peter A W, Te Boekhorst, Martin R, Schipperus, Jaap Jan, Zwaginga, Lizzy C M, van Pampus, Georgine E, de Greef, Marleen, Luten, Peter C, Huijgens, Anneke, Brand, Dick J, van Rhenen
Publikováno v:
British journal of haematology. 150(2)
Pathogen reduction (PR) of platelet products increases costs and available clinical studies are equivocal with respect to clinical and haemostatic effectiveness. We conducted a multicentre, open-label, randomized, non-inferiority trial comparing the
Autor:
Jaap Jan Zwaginga, Peter C. Huijgens, Viera M.J. Novotny, Jean-Louis H. Kerkhoffs, Georgine E. de Greef, Peter A. W. te Boekhorst, Dick J. van Rhenen, Lizzy C.M. van Pampus, Martin R. Schipperus, Anneke Brand, Wim L.J. van Putten, Marleen Luten
Publikováno v:
British Journal of Haematology.
Pathogen reduction (PR) of platelet products increases costs and available clinical studies are equivocal with respect to clinical and haemostatic effectiveness. We conducted a multicentre, open-label, randomized, non-inferiority trial comparing the
Publikováno v:
Transfusion, 50, 2, pp. 366-75
Transfusion, 50, 366-75
Transfusion, 50, 366-75
Contains fulltext : 87371.pdf (Publisher’s version ) (Closed access) BACKGROUND: To maintain a high quality of red blood cells (RBCs), RBC characteristics must be followed during storage under blood bank conditions. By means of infrared (IR) spectr
Autor:
Willem J. de Grip, Bregt Roerdinkholder-Stoelwinder, Edwin Lasonder, Marleen Luten, Věra M.J. Novotný, Giel J. C. G. M. Bosman, Harry J Bos
Publikováno v:
Transfusion, 48, 5, pp. 827-35
Transfusion, 48, 827-35
Transfusion, 48, 827-35
Contains fulltext : 70689.pdf (Publisher’s version ) (Closed access) BACKGROUND: During storage of red cells (RBCs) for transfusion, RBCs undergo a number of biochemical and morphologic changes. To be able to identify the mechanisms underlying thes
Autor:
Willem J. de Grip, Bregt Roerdinkholder-Stoelwinder, Giel J. C. G. M. Bosman, Nicolaas Schaap, Harry J Bos, Marleen Luten
Publikováno v:
Transfusion, 48, 7, pp. 1478-85
Transfusion, 48, 1478-85
Transfusion, 48, 1478-85
Contains fulltext : 70886.pdf (Publisher’s version ) (Closed access) BACKGROUND: The use of fresh red blood cells (RBCs) is recommended for critically ill patients and patients undergoing surgery, although there is no conclusive evidence that this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29136a1336267b57124f41ebbae5e7cf
https://hdl.handle.net/2066/70886
https://hdl.handle.net/2066/70886